Doctors Without Borders/Médecins Sans Frontières (MSF) will participate in an ongoing randomized controlled trial of four potential Ebola treatments in North Kivu, Democratic Republic of Congo, in collaboration with the Ministry of Health, the international medical humanitarian organization said Tuesday.
Historically, 60–70 percent of patients infected with Ebola virus in central African countries have died.
mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings.
In Congo, more than 600 people have contracted the Ebola virus which has claimed close to 400 lives.
The team of scientists demonstrated that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections of caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain.
More than half of the patients who received treatment survived, scientists reported.
Two of the first 16 people to receive an experimental treatment for Ebola have recovered in the current outbreak in North Kivu and Ituri provinces of the Democratic Republic of Congo.
The four additional treatments approved by Congo’s ethics committee are Remdesivir, made by Israel’s Gilead Sciences; ZMapp, an intravenous treatment made by San Diego’s Mapp Pharmaceutical; Japanese drug Favipiravir; and one referred to as Regn3450 – 3471 – 3479.
This intermediate level course is for clinicians caring for patients with suspected or confirmed Ebola virus disease. Modules provide information on screening and triage, infection prevention and control, laboratory diagnostics, organization of the Ebola Treatment Centre (ETC), clinical care of patients in the ETC, and investigational therapeutic agents.
On June 4, the Democratic Republic of the Congo approved the use of favipiravir, a drug originally developed to fight influenza, for treating Ebola patients.